Emerging blood-based biomarkers for detection of gastric cancer

Abstract

Early detection and efficient monitoring of tumor dynamics are prerequisites for reducing disease burden and mortality, and for improving the management of patients with gastric cancer (GC). Blood-based biomarker assays for the detection of early-stage GC could be of great relevance both for population-wide or risk group-based screening programs, while circulating biomarkers that reflect the genetic make-up and dynamics of the tumor would allow monitoring of treatment efficacy, predict recurrences and assess the genetic heterogeneity of the tumor. Recent research to identify blood-based biomarkers of GC has resulted in the identification of a wide variety of cancer-associated molecules, including various proteins, autoantibodies against tumor associated antigens, cell-free DNA fragments, mRNAs and various non-coding RNAs, circulating tumor cells and cancer-derived extracellular vesicles. Each type of these biomarkers provides different information on the disease status, has different advantages and disadvantages, and distinct clinical usefulness. In the current review, we summarize the recent developments in blood-based GC biomarker discovery, discuss the origin of various types of biomarkers and their clinical usefulness and the technological challenges in the development of biomarker assays for clinical use.

The biomarker landscape in mycosis fungoides and Sézary syndrome

“…[11] We propose four functions biomarkers can perform in MF/SzS: Biomarkers used for screening purposes must be inexpensive, easily and robustly measurable using minimally invasive routine laboratory techniques, and should discriminate between malignant and benign processes. Early-stage MF may be confused with benign inflammatory conditions such as psoriasis, eczema or other dermatoses (e.g.…”

“…[11] These markers are used for detecting occult recurrences in patients who are in clinical remission and for monitoring response to therapy.…”

Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer

“…High cure rates are achieved for stage IA and IB gastric cancer, but the results for advanced stages IIIA and IIIB are poor, and a high percentage of patients are locally irresectable at time of diagnosis (93,94). Five-year overall survival rates in patients diagnosed with advanced or metastatic disease are not exceeding 20% (95). Multimodal treatment involving surgery, chemotherapy and radiotherapy have been the mainstay in the treatment of gastric cancer.…”

Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin

“…Gastric cancer is the fifth most common malignancy and the third leading cause of cancer-associated mortality worldwide (1). According to GLOBOCAN 2012, ~1 million new gastric cancer cases, with an ~72% mortality rate, were diagnosed in 2012, of which ~50% occurred in Eastern Asia (predominantly in China) (2).…”